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Abstract
We constructed a large-scale functional network model in Drosophila melanogaster built around
two key transcription factors involved in the process of embryonic segmentation. Analysis of the
model allowed the identification of a new role for the ubiquitin E3 ligase complex factor SPOP. In
Drosophila, the gene encoding SPOP is a target of segmentation transcription factors. Drosophila
SPOP mediates degradation of the Jun-kinase phosphatase Puckered thereby inducing TNF/Eiger
dependent apoptosis. In humans we found that SPOP plays a conserved role in TNF-mediated JNK
signaling and was highly expressed in 99% of clear cell renal cell carcinoma (RCC), the most
prevalent form of kidney cancer. SPOP expression distinguished histological subtypes of RCC and
facilitated identification of clear cell RCC as the primary tumor for metastatic lesions.
Over the last three decades, extensive molecular and genetic analyses have characterized the
identity of and interactions between components of the Drosophila segmentation process (1).
Maternal factors distributed in gradients along the anterior-posterior (A-P) axis activate zygotic
transcription of gap genes, which encode transcription factors that activate sets of pair-rule
genes including the homeobox transcription factors Even-skipped (Eve) and Fushi tarazu (Ftz).
These pair rule proteins then directly regulate segment polarity genes that determine the internal
A-P orientation of each segment. Many of the human homologs of these genes and their down-
stream targets play critical roles in human diseases, especially cancers (2,3). In an effort to
extract new information from the Drosophila segmentation network, as well as to mine this
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network for novel disease related genes, we built a large-scale predictive network model around
Ftz and Eve.
We analyzed gene expression changes between individual wild type embryos and embryos
with null mutations in ftz and eve (4,5) collected during a developmental time course from 2
hr until 7 hr after egg laying (AEL). By focusing on Ftz and Eve effects 2 to 3 hours AEL (early
zygotic expression), we found 1310 genes differentially expressed between the ftz mutant and
wild type, and 1074 genes differentially expressed between the eve mutant and wild type (false
discovery rate < 0.001, table S1, S2).
Using antibodies specific for Ftz or Eve, we performed chromatin immunoprecipitation (ChIP)
and mapped genome-wide transcription factor binding in cellular blastoderm embryos 2 hours
AEL on custom designed high density DNA microarrays (4). We found 1286 Ftz and 1499
Eve bound probes (intensity P < 0.0001 and Z score > 1.96, see supplemental method; 21 probes
on both lists map within 500bp). We analyzed several methods for probe to target gene mapping
to maximize the overlap between the differentially expressed and ChIP target gene sets (see
supplemental methods; fig. S1). The greatest such enrichment was obtained by designating
genes within 1kb of a binding site as targets. At this threshold, we identified 969 Ftz ChIP-
chip target genes and 932 Eve ChIP-chip target genes (overlap 175 genes; table S3, S4).
Genes both differentially expressed and targeted by ChIP-chip binding site mapping were
considered as putative direct target genes. We thus identified 137 Ftz direct target genes (Fig.
1A) and 98 Eve direct target genes (fig. S2; overlap 9 genes). Fig. 1A (right panel) shows the
locations of binding sites at Ftz or Eve direct target genes. Analysis of direct target gene
annotations indicates 39 genes (21%) regulate transcription and 74 genes (40%) are involved
in developmental processes (Fig. 1A, center panel); both annotation classes were significantly
enriched compared to the 9.6% and 18% of Drosophila genes annotated as transcriptional or
developmental regulators, respectively (p=1.05×10−6 and p=1.81×10−12; hypergeometric test).
A complete target list can be found in tables S5 and S6.
To extend our Ftz-Eve network model beyond direct transcriptional regulation, we included
automated literature mining methods to capture published interactions of target genes (5). We
then integrated yeast two-hybrid based protein-protein interaction data (6) into our model by
connecting protein interactions between existing components in the network. To limit the size
of the network, we extended the protein-protein interaction only one degree from the direct
targets of Ftz or Eve. The resulting Ftz-Eve regulatory network model included 4084 genes/
proteins and 6648 interactions between them (fig. S3).
To confirm parts of the network model topology we examined several genes that are expressed
in segmental patterns (7) and validated a limited set of interactions by genetic and biochemical
testing of simple predictions from our network model (fig. S4),
Analysis of the Eve-Ftz network identified 150 different genes as direct targets of Eve or Ftz
that also have unambiguous human homologs. From this gene set, we identified a top candidate,
CG9924 or roadkill (rdx), which ranks first in network betweenness-centrality and thus
constitutes a major network hub (8) (see supplemental methods, table S8). The rdx gene
encodes a BTB domain protein that has been recently shown to act to regulate Cubitus
interruptus (Ci) degradation in the Hedgehog pathway (9,10). This product of the rdx gene is
79% identical to the human protein SPOP and these proteins appear to be orthologs (fig. S5)
(9,10); we refer to the rdx gene product(s) as Drosophila SPOP (D-SPOP).
Our network model indicates that the D-SPOP gene is a direct target of Ftz at 2–3 hours AEL
and that the D-SPOP protein interacts with the Jun Kinase phosphatase Puckered (Puc) (Fig.
1B). RNA in situ hybridizations for D-SPOP mRNA in ftz mutant embryos confirmed that ftz
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is indeed required for D-SPOP expression in parasegments that normally express Ftz (Fig. 1C).
We did not observe significant mis-expression of D-SPOP mRNA in eve mutant embryos at
2–3 hours AEL (fig. S6), suggesting that the Ftz effects on D-SPOP mRNA levels occurs in
advance of the Eve effect. We found that the D-SPOP protein segmental expression pattern
was completely lost in eve mutant embryos 6–7 hours AEL (Fig. 1D), behaving similarly to
the well-characterized Ftz and Eve target gene engrailed (11,12). Previous studies also indicate
that D-SPOP is regulated by Hedgehog (Hh) later in development, indicating another layer of
D-SPOP regulation by the segment polarity system (9). Together, these data strongly indicate
that D-SPOP expression is downstream of the pair-rule genes in the segmentation hierarchy.
RNAi knockdown of D-SPOP mRNA levels and P-element insertion mutagenesis of the D-
SPOP gene resulted in severe and consistent disruption of both the peripheral and the central
nervous system (CNS) (fig. S7). Such phenotypes are recapitulated by mutating ftz or eve and
are likely due to mid-embryonic functions of D-SPOP when Ftz and Eve become active in the
CNS (13,14). Furthermore, it was recently demonstrated that the Drosophila Eiger/TNF
pathway regulates embryonic neuroblast division (15). Thus we hypothesized that the function
of D-SPOP in nervous tissue development may result from its interaction with Puc, which
mediates a feedback loop by negatively regulating basket (Drosophila JNK) in the
Drosophila Eiger/Tumor Necrosis Factor (TNF) pathway (16) (Fig. 1B).
In Drosophila, ectopic expression of Eiger in neuronal cells in the developing eye induces
apoptosis through the JNK pathway, resulting in a reduced adult eye size (Fig. 2A, 2B) (17).
Deletion of one wild-type copy of D-SPOP or RNAi knock down of D-SPOP mRNA partially
suppresses the eye phenotype of Eiger expression (Fig. 2C, 2D). Additionally, ectopic
expression of D-SPOP in the developing eyes produces a small and rough eye phenotype (Fig.
2E). Analysis of genetic interactions between the genes encoding D-SPOP and other members
of the Eiger-JNK pathway (fig. S8), indicates that D-SPOP is acting downstream of dTAK1
(JNKKK) and Hep (JNKK) and upstream of Bsk (JNK) and Puc. Our experiments therefore
indicate that D-SPOP functions as an essential positive regulator for Eiger triggered apoptosis,
consistent with the interaction between D-SPOP and Puc predicted in the Ftz-Eve network
model.
A physical interaction between D-SPOP and Puc was confirmed by both in vitro pulldown and
in vivo immunoprecipitation assays (Fig. 2F, 2G). D-SPOP contains two conserved domains,
a MATH domain and a BTB/POZ domain (18). MEL-26, the Caenorhabditis elegans ortholog
of human SPOP, was first identified as a BTB protein that serves as an adaptor of Cul3 based
ubiquitin ligase (18). Recently, human SPOP has been shown to mediate ubiquitination of
death domain-associated protein (Daxx) (19), the Polycomb group protein BMI-1, the histone
variant MacroH2A (20), and the transcription factor Gli (10). We found that Puc protein levels
were significantly reduced when co-expressed with D-SPOP in S2 cells (Fig. 2H). Furthermore,
D-SPOP promoted Puc ubiquitination in S2 cells treated with the proteasome inhibitor MG132
(Fig. 2I). Taken together, these results indicate that D-SPOP induces apoptosis in the Eiger/
TNF pathway by the mediating Puc ubiquitination and degradation (Fig. 2J).
Homologs of several Ftz and Eve targets have been shown to be involved in human cancers
(21), a large body of experimental and clinical data indicates that defects in ubiquitin signaling
pathways have roles in the genesis of different tumor types (22), and JNK activation is required
for cellular transformation induced by RAS, an oncogene mutated in 30% of human cancers
(23). To determine whether human SPOP’s role in modulating TNF stimulated JNK signaling
is conserved, we treated HEK293 cells over-expressing SPOP with TNF-α, then analyzed
phosphorylated JNK (P-JNK) and phosphorylated c-Jun (P-c-Jun) levels. Consistent with its
role in Drosophila as an activator of the pathway, overexpression of SPOP increases the level
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of P-JNK and P-c-Jun, indicating conservation of its function in modulating the JNK pathway
(Fig. 3A).
To test whether SPOP is associated with human cancers, SPOP protein expression levels were
screened with tissue microarrays that contained 20 tumors from each of 18 different organs.
We found that 85% of renal cell carcinomas (RCC) showed high expression of SPOP, while
normal kidney tissue was uniformly negative (Fig 3B; Table 1). To further investigate the
potential of SPOP as a marker, we designed a large tissue array containing more than 300 RCC
samples. 77% of the tumor samples were positive for SPOP staining; normal kidney samples
were all negative (Table 2).
RCC is a heterogeneous group of tumors with distinct histological subtypes, including clear
cell, papillary, chromophobe and other rare subtypes in addition to oncocytoma, which is a
benign solid renal tumor (24). The majority of RCC is of clear cell type, comprising up to 75%.
While the majority of RCCs can be subtyped by hematoxylin + eosin staining morphology,
diagnostic difficulties arise when clear cell RCCs display morphologic features that overlap
with other RCC subtypes and non-renal tumors (25–27). Currently, a panel of
immunohistochemical markers is used to differentiate the major subtypes of RCC in difficult
cases (26,27). Unfortunately, these panels lack a specific and sensitive marker that is positive
in clear cell RCC (26,27). Recently Carbonic Anhydrase IX has been proposed as a positive
marker for clear cell RCC, but it is positive in other RCCs and several other tumor types as
well (28–30). Patient tumor samples in our studies were classified into different types according
to the recent World Health Organization (WHO) classification system. We found that 99% of
the clear cell RCC and 86% of the chromophobe RCC showed positive staining for SPOP, but
only 22% of papillary-type RCC were SPOP positive. Four out of 31 papillary RCCs from the
general pathology reports were shown to be misdiagnosed as clear cell RCCs when the tumor
biopsies were re-analyzed by urological pathologists. All four of these misdiagnosed RCCs
have papillary architecture and were subsequently shown to stain positive for SPOP. Our tissue
array also included benign oncocytomas, which can mimic renal cell carcinoma both clinically
and pathologically, in turn potentially subjecting patients to unnecessary surgeries and
additional morbidities. Only 6% of oncocytomas showed weak positive staining. These results
indicate that SPOP is a highly sensitive and specific diagnostic biomarker for clear cell RCC
and can help distinguish histological subtypes of RCC.
Up to 30% of RCC patients present with metastases; half of the rest will develop metastases
later in their course, 90% of which are clear cell RCCs. Accordingly, we further screened for
SPOP staining in confirmed metastases from RCC and found that 97% of them were positive
(Table 3), indicating that SPOP may be a useful biomarker to identify clear cell RCC as the
site of the primary tumors in cases of metastases from unknown origin. Taken together, our
results demonstrate that novel functions for conserved molecules can readily be extracted from
data mining of large scale networks in Drosophila, and provide a strategy for rapid
identification of factors that may have clinical relevance as biomarkers or drug targets for
human diseases.
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Drosophila segmentation network. (A) Identification of direct targets of Ftz. Heatmap at left
depicts log2-fold change in gene expression, mutant vs. wild type. Columns represent time
points in hours after egg laying (AEL). Rows depict individual genes, sorted by hierarchical
clustering. Genes involved in regulation of development (left tick marks) or transcriptional
regulation (right tick marks) from gene ontology (GO) annotations are marked in the center
panel. Locations of binding sites relative to the transcription start site of each gene are
represented at right. (B) Detailed D-SPOP subnetwork depicting that D-SPOP is regulated by
FTZ and EVE and interacts with puc. (C) RNA in situ hybridization of D-SPOP in wild type
and ftz mutant backgrounds. 14 and 7 stripes of expression were observed in wild type and
ftz embryos, respectively. (D) D-SPOP and EVE antibody staining in wild type and eve mutant
backgrounds. D-SPOP (BCIP/NBT, blue) was stained in segmental grooves in wild type but
all expression was lost in eve mutant embryos. Eve (Diaminobenzidine, brown) was stained in
neurons.
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D-SPOP promotes puc ubiquitination and degradation. (A) Light micrographs of Drosophila
adult eyes for wild type (GMR-Gal4/+). (B) GMR>Egr triggered cell death and produced a
small eye phenotype (GMR-Gal4 UAS-Egr/+). (C) Deleting one copy of D-SPOP (GMR-Gal4
UAS-Egr/+; D-SPOPΔ6/+) suppressed the phenotype of (GMR-Gal4 UAS-Egr/+). (D) Co-
expression of D-SPOP RNAi (GMR-Gal4 UAS-Egr/+; UAS-D-SPOP-RNAi) suppressed the
phenotype of (GMR-Gal4 UAS-Egr/+). (E) Expression of D-SPOP (GMR-Gal4 UAS-D-SPOP/
+) produced rough eyes with slightly reduced size. (F) D-SPOP interacts with Puc in an in
vitro affinity assay. Proteins were translated in vitro, purified on a nickel ion (Ni++) column
and detected by Western blot (see supplementary methods). Lane 1, His-Puc; Lane 2, His-D-
SPOP; Lane 3, untagged D-SPOP co-purifies with His-Puc; Lane 4, untagged Puc co-purifies
with His-D-SPOP. (G) D-SPOP interacts with Puc in an in vivo immunopreciptation (IP) assay.
IPs were carried out with anti-HA antibody using cell lysates from S2 cells expressing the
indicated fusion proteins, followed by immunoblot with anti-Myc epitope antibody. Lane 1,
IP of HA-D-SPOP control transfection shows only the IgG band; Lane 2, IP of HA-D-SPOP
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in cells co-transfected with Myc-Puc, which is detected as two bands. (H) Puc degradation is
promoted by SPOP. Western blots were performed with anti-Myc antibody to detect Myc-Puc
fusion protein. Lane 1, HA-Ubiquitin (HA-Ub) transfection negative control; Lane 2, Myc-
Puc transfection positive control; Lane 3, Myc-Puc and D-SPOP co-transfection shows
reduction of Myc-Puc levels relative to. Tubulin is detected as a loading control. (I) In vivo
ubiquitination of Puc is promoted by D-SPOP. Myc-Puc was detected by immunoblot with
anti-Myc epitope antibody. Lane 1, HA-Ub expression and MG132 treatment as a negative
control; Lane 2, HA-Ub and Myc-Puc co-expression with MG132 treatment but without D-
SPOP; Lane 3, Myc-Puc levels decreased with co-expression of HA-Ub and D-SPOP but
without addition of MG132; Lane 4, Myc-Puc poly-ubiquitination in the presence of HA-Ub,
D-SPOP and MG132. (J) TNF/Eiger induced apoptosis pathway. D-SPOP (pink) is
downstream of dTAK1 (JNKKK, yellow) and Hep (JNKK, yellow), and upstream of Bsk
(DJNK, green) and Puckered (MKP, green).
Liu et al. Page 8














Function of SPOP in the mammalian TNF pathway and over-expression in renal cell carcinoma.
(A) Over-expression of SPOP increases the level of P-JNK and P-c-Jun. Human embryonic
kidney (HEK293) cells were transfected with SPOP, treated with 50ng/ml TNF at 0, 5, 15, 30,
60 minutes, followed by immunoblot. In control treatments, HEK293 cells were transfected
with empty pcDNA3.1 vector, and thus only express endogenous levels of SPOP. (B) SPOP
expression in RCC tissue. Tissue images are from normal kidney, oncocytoma and clear cell
renal carcinoma. A SPOP-specific monoclonal antibody (SPOP-5G) was used to detect SPOP
expression in tissue (Diaminobenzidine, brown staining).
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Table 1
Tissue micro-array screening for SPOP expression in 18 cancer types from different organs.
Tissue Type Normal Tissue Cancer Tissue
Kidney/Renal 5 negative 17 positive; 3 negative
Uterus/Endometrial 5 negative 10 positive; 4 negative
Testis/Germ cell 5 weak 18 positive; 2 negative
Soft tissue/Sarcoma 5 negative 20 weak or negative
Lung 5 weak 20 weak
Bladder 5 weak or negative 20 weak or negative
Breast 5 weak or negative 20 weak or negative
Prostate 5 negative 1 positive; 19 negative
Pancreas 5 negative 20 negative
Lymphoma 5 negative 19 weak or negative
Thyroid 5 negative 20 weak or negative
Colon 5 negative 20 negative
Ovary 5 weak or negative 20 weak or negative
Skin/Melanoma 5 weak or negative 20 weak or negative
Liver 5 positive 7 positive; 13 negative
Skin/squamous 5 weak or negative 20 weak or negative
Brain 5 weak or negative 20 weak or negative
Stomach/Gastric 5 weak or negative 20 weak or negative
SPOP is highly expressed in renal cell carcinoma as compared to normal renal tissue. Endometrial carcinoma and germ cell tumors also display higher
SPOP staining relative to comparable normal tissues.













Liu et al. Page 11
Table 2
SPOP expression in RCCs. RCC tissue sections were analyzed by staining with SPOP specific monoclonal antibody
(SPOP-5G). Patient samples are classified into different categories depending on cell type.
Renal cell type positive negative




rare type 6 8
Total tumor 199 59
Normal tissue 0 295
*
Both cases are weak staining.
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Table 3
SPOP expression in metastatic lesions where RCC were the primary tumors. Metastatic tissues were analyzed by
staining with SPOP specific monoclonal antibody (SPOP-5G). Patient samples are classified into different categories
depending on cell type of the primary tumor.
Primary RCC type positive negative
clear cell 71 2
chromophobe 3 1
papillary 1 2
rare type 3 4
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